Division of Teva Pharmaceutical Industries Ltd.
Latest From Actavis Laboratories
A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.
A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Actavis’ a.k.a. Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.
Having decided that generics must reference reformulated OxyContin, the agency must determine the evidence needed for generics to show they provide equivalent abuse-deterrence.
OxyContin’s method of treatment patent expires April 16, but several patents remain tied up in litigation over APIs as Purdue and generic companies await FDA decision on whether the original formulation can be a reference product.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Andrx Corp.
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
Nicholas F Cappuccino, PhD, EVP, CSO
Jeffrey Long-McGie, VP, Bus. Dev.
- Contact Info
Phone: (954) 382-7600
8151 Peters Rd.
Davie, FL 33314
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.